Neurol. praxi. 2022;23(5):373-378 | DOI: 10.36290/neu.2022.054

High-efficacy drugs in early stage of multiple sclerosis

MUDr. Veronika Tichá, Ph.D.
Neurologická klinika a Centrum klinických neurověd, 1. LF UK a VFN v Praze

The most commonly used treatment algorithm in multiple sclerosis (MS) is initiation with lower efficacy drugs, i.e. first-choice drugs, and, in case of their failure, escalation to drugs with higher efficacy, also known as HET (High Efficacy Treatment). The use of high-efficacy drugs at an early stage of the disease, however, appears to be a superior strategy in delaying progression and irreversible damage to the central nervous system. The favourable safety profile of these drugs allows to aim, from the very beginning of MS treatment, at complete stabilization of clinical parameters and of the finding on magnetic resonance imaging. However, the complicated and confusing system of restrictive reimbursement criteria is an obstacle to using high-efficacy drugs freely.

Keywords: multiple sclerosis, early stage, escalation therapy, high-efficacy treatment

Received: August 14, 2022; Revised: August 14, 2022; Accepted: August 31, 2022; Prepublished online: August 31, 2022; Published: October 6, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Tichá V. High-efficacy drugs in early stage of multiple sclerosis. Neurol. praxi. 2022;23(5):373-378. doi: 10.36290/neu.2022.054.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Alping P, Burman J, Lycke J, et. al. Safety of Alemtuzumab and Autologous Hematopoietic Stem Cell Transplantation Compared to Noninduction Therapies for Multiple Sclerosis. Neurology. 2021;96(11):e1574-e1584. doi: 10.1212/WNL.0000000000011545. Epub 2021 Jan 29. Go to original source... Go to PubMed...
    2. Ayrignac X, Bigaut K , Pelletier J, et al. First line treatment failure: Predictive factors in a cohort of 863 Relapsing Remitting MS patients. Mult Scler Relat Disord. 2021;48:102686. doi: 10.1016/j.msard.2020.102686. Epub 2020 Dec 13. Go to original source... Go to PubMed...
    3. Barkhof F, de Jong R, Sfikas N, de Vera A, Francis G, Cohen J, et al. The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing­‑Remitting Multi- ple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis. Mult Scler. 2014;20:1704-13. Go to original source... Go to PubMed...
    4. Benkert P, Meier S, Schaedelin S, et al. Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. Lancet Neurol. 2022;21:246-57. Go to original source... Go to PubMed...
    5. Brown JW, Coles A, Horakova D, et al. Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. JAMA. 2019;321(2):175-187. doi: 10.1001/jama.2018.20588. Go to original source... Go to PubMed...
    6. . Brown JWL, Coles A, Horakova D, et al. Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. JAMA. 2019; 321(2):17-187. Published online 2019 Jan 15. doi: 10.1001/jama.2018.20588. Go to original source... Go to PubMed...
    7. Buron MC, Chalmer TA, Sellebjerg F, et al. Initial high-efficacy disease-modifying therapy in multiple sclerosis: A nationwide cohort study. Neurology. Published Ahead of Print on July 7, 2020 as 10.1212/WNL.0000000000010135. Go to original source... Go to PubMed...
    8. Burt RK, Balabanov R, Burman J, et. al. Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis. A Randomized Clinical Trial. JAMA. 2019;321(2):165-174. doi: 10.1001/jama.2018.18743. Go to original source... Go to PubMed...
    9. Cohen JA, Barkhof F, Comi G, et al. Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. J Neurol. 2013;260:2023-32. Go to original source... Go to PubMed...
    10. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl Med. 2010;362:402-15. Go to original source... Go to PubMed...
    11. Dekker I, Sombekke MH, Balk LJ, et al. Infratentorial and spinal cord lesions: Cumulative predictors of long-term disability? Mult Scler Journal. 2019;XXXX. Go to original source...
    12. Edan G, Miller D, Clanet M, et. al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J of Neurology, Neurosurgery, and Psychiatry. 1997;62:112-118. Go to original source... Go to PubMed...
    13. Edan G, Comi C, LePage E, et al. Mitoxantrone prior to interferon-beta-1b in aggressive relapsing multiple sclerosis: a3-year randomised trial. J of Neurology, Neurosurgery, and Psychiatry. 2011;82:1344e1350. doi:10.1136/jnnp.2010.229724. Go to original source... Go to PubMed...
    14. European Medicines Agency. Lemtrada assessment report: procedure under article 20 of regulation (EC) No 726/2004 resulting from pharmacovigilance data. 2019. https://www.ema.europa.eu/. Accessed 12 Aug 2020.
    15. Filippi M, Danesi R, Derfuss T, et al. Early and unrestricted access to highefcacy diseasemodifying therapies: a consensus to optimize benefts for people living with multiple sclerosis. Journal of Neurology. 2022;269:1670-1677. https://doi.org/10.1007/s00415-021-10836-8 1 3. Go to original source... Go to PubMed...
    16. He A, Merkel B, Brown JWL. Timing of high-efficacy the­rapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol. 2020;19(4):307-316. doi: 10.1016/S1474-4422(20)30067-3. Epub 2020 Mar 18. Go to original source... Go to PubMed...
    17. Hutchinson M, Kappos L, Calabresi PA, et al. The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol. 2009;256:405-15. Go to original source...
    18. Khatri B, Barkhof F, Comi G, et al. Comparison of fingolimod with interferon beta-1a in relapsing­‑remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol. 2011;10:520-9. Go to original source... Go to PubMed...
    19. Le Page E, Edan G. Induction or escalation therapy for patients with multiple sclerosis? Rev Neurol (Paris). 2018;174(6):449-457. doi: 10.1016/j.neurol.2018. 04. 004. Epub 2018 May 22. Go to original source... Go to PubMed...
    20. Mariottini A, De Matteis E, Muraro PA. Haematopoietic Stem Cell Transplantation for Multiple Sclerosis: Current Status. BioDrugs. 2020;34:307-325. https://doi.org/10.1007/s40259-020-00414-1. Go to original source... Go to PubMed...
    21. Merkel B, Butzkueven H, Traboulsee AL, et al. Timing of high­‑efficacy therapy in relapsing­‑remitting multiple sclerosis: A systematic review. Autoimmunity Reviews. 2017;16: 658-665. Go to original source... Go to PubMed...
    22. Montalban X, Gold R, Thompson AJ, et al. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler. 2018;24:96-120. Go to original source... Go to PubMed...
    23. Novantrone. Souhrn údajů o přípravku. [online]. Available from: https://www.ema.europa.eu/en/documents/referral/novantrone-article-30-referral-annex-iii_en.pdf.
    24. Silviera F, Sánchez F, Miguez J, et al. New MRI lesions and topography at 6 months of treatment initiation and disease activity during follow up in relapsing remitting multiple sclerosis patients. Neurol Res. 2020;42(2):148-152. doi: 10.1080/01616412.2019.1710415. Epub 2020 Jan 20. Go to original source... Go to PubMed...
    25. Sorensen PS, Sellebjerg F. Pulsed immune reconstitution therapy in multiple sclerosis. Ther Adv Neurol Disord. 2019;12:1756286419836913. doi: 10.1177/1756286419836913. eCollection 2019. Go to original source...
    26. Srpova B, Uher T, Hrnciarova T, et al. Serum neurofilament light chain reflects inflammation­‑driven neurodegeneration and predicts delayed brain volume loss in early stage of multiple sclerosis, Mult Scler. 2021;27(1):52-60. doi: 10.1177/1352458519901272. Epub 2020 Jan 21. Go to original source... Go to PubMed...
    27. Stankiewicz JM, Wiener HJ. An argument for broad use of high efficacy treatments in early multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2019;7(1). doi: 10.1212/NXI.0000000000000636. Print 2020 Jan. Go to original source... Go to PubMed...
    28. Syed YY. Alemtuzumab: A Review in Relapsing Remitting Multiple Sclerosis. Drugs. 2021;81:157-168. https://doi.org/10.1007/s40265-020-01437-2. Go to original source... Go to PubMed...
    29. Turner B, Cree BAC, Kappos L, et al. Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. Journal of Neurology. https://doi.org/10.1007/s00415-019-09248-6 Go to original source... Go to PubMed...
    30. Ziemssen T, Engelmann U, Jahn S, et al. Rationale, design, and methods of a non­‑interventional study to establish safety, effectiveness, quality of life, cognition, health­‑related and work capacity data on Alemtuzumab in multiple sclerosis patients in Germany (TREAT­‑MS). BMC Neurol. 2016;16:109. Published online 2016 Jul 19. doi: 10.1186/s12883-016-0629-9. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.